omectatug + tislelizumab + oxaliplatin + capecitabine

**Omectatug + tislelizumab + oxaliplatin + capecitabine** is an investigational combination regimen being evaluated for the first-line treatment of claudin 18.2 (CLDN18.2)-positive, HER2-negative advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The regimen combines targeted therapy, immunotherapy, and cytotoxic chemotherapy to maximize anti-tumor efficacy. **Omectatug** (ASKB589) is a humanized IgG1 monoclonal antibody that targets CLDN18.2, a tight junction protein overexpressed in gastric cancers, inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). **Tislelizumab** is an anti-PD-1 monoclonal antibody designed to block the interaction between PD-1 and its ligands, thereby restoring T-cell-mediated anti-tumor immune responses. **Oxaliplatin** (a platinum-based alkylating agent) and **capecitabine** (an oral fluoropyrimidine carbamate prodrug of 5-fluorouracil) constitute the CAPOX chemotherapy backbone, which induces DNA damage and cell death in rapidly dividing cancer cells. This quadruple combination is being developed by AskGene Pharma and its parent company, Jiangsu Aosaikang Pharmaceutical, and is currently in Phase III clinical trials.

Other names

ASKB-589 + CAPOX + tislelizumabASKB-589 + Tevimbra + CAPOXASKB-589 + Tevimbra + capecitabine + oxaliplatinASKB-589 + tislelizumab + CAPOXASKB-589 + tislelizumab + capecitabine + oxaliplatinASKB589 + CAPOX + tislelizumabASKB589 + Tevimbra + CAPOXASKB589 + Tevimbra + capecitabine + oxaliplatinASKB589 + tislelizumab + CAPOXASKB589 + tislelizumab + capecitabine + oxaliplatinomectatug + CAPOX + tislelizumabomectatug + Tevimbra + CAPOXomectatug + Tevimbra + capecitabine + oxaliplatinomectatug + tislelizumab + CAPOX